These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 21285923)

  • 21. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X
    Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
    Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
    J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
    Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
    Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
    Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
    Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
    Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R; Kand P; Basu S
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
    Kim SJ; Lee TH; Kim IJ; Kim YK
    Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
    Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.